Mirum Pharmaceuticals, Inc.
A pharmaceutical company focused on rare diseases, it markets three FDA-approved medicines: Livmarli for the severe itching of certain inherited liver conditions, Ctexli for cerebrotendinous xanthomatosis, and Cholbam for bile acid disorders. It was founded in 2018 by a team that revived its lead drug after pharmaceutical giant Shire set it aside, and its name comes from Latin, meaning "wonder" or "marvel."
Granted 5.7K · Bought 300.1K
Granted 366.8K · Sold 276.0K
Granted 164.6K · Sold 164.6K
Granted 31.2K · Sold 33.2K
Granted 434 · Sold 1.9K
Granted 83.4K · Sold 62.7K
Granted 65.0K · Bought 14.0K · Sold 32.3K
Granted 22.7K · Sold 17.0K
Granted 41.8K · Sold 23.0K
Granted 4.0K
Granted 9.7K
Granted 9.7K
Granted 96.3K · Sold 90.5K
Granted 5.7K · Sold 3.2K
Granted 51.2K · Sold 51.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Heron Patrick JDirector · 20 transactions | — | 4.03M | 5.7K | 300.1K | — |
| Peetz ChristopherCHIEF EXECUTIVE OFFICER, Director · 35 transactions | +29.1% | 409.2K | 366.8K | — | 276.0K |
| Grey Michael GDirector · 11 transactions | -17% | 330.2K | 164.6K | — | 164.6K |
| Vig PamelaCHIEF SCIENTIFIC OFFICER · 6 transactions | +25.7% | 133.0Kas of Jun 2024 | 31.2K | — | 33.2K |
| Longpre LaraCHIEF DEVELOPMENT OFFICER · 3 transactions | -1.4% | 104.4Kas of Feb 2024 | 434 | — | 1.9K |
| Radovich PeterPRESIDENT AND COO · 22 transactions | +52% | 57.3K | 83.4K | — | 62.7K |
| Bjerkholt EricCHIEF FINANCIAL OFFICER · 21 transactions | — | 47.2K | 65.0K | 14.0K | 32.3K |
| Brege LauraDirector · 4 transactions | +227% | 32.7K | 22.7K | — | 17.0K |
| Quan JoanneCHIEF MEDICAL OFFICER · 9 transactions | — | 18.9K | 41.8K | — | 23.0K |
| Fischer LaurentDirector · 1 transaction | +58.9% | 10.7K | 4.0K | — | — |
| Cardon LonDirector · 2 transactions | — | 9.7K | 9.7K | — | — |
| Walbert Timothy PDirector · 2 transactions | — | 9.7K | 9.7K | — | — |
| Howe JolandaSVP, GLOBAL CONTROLLER · 38 transactions | — | 5.8K | 96.3K | — | 90.5K |
| Fairey WilliamDirector · 2 transactions | — | 2.5Kas of Jun 2025 | 5.7K | — | 3.2K |
| Ramasastry SairaDirector · 25 transactions | — | 0 | 51.2K | — | 51.2K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -441.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.